Epileptic Encephalopathy clinical trials

Explore recruiting epileptic encephalopathy clinical trials.

Recruiting epileptic encephalopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Epileptic Encephalopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase Ib/II first-in-human, multicentre, open-label, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of intrathecal S230815 in paediatric participants with KCNT1-related Developmental and Epileptic Encephalopathy

France, Italy, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathies

Portugal, Netherlands, Germany, France, Spain, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy

Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Double-Blind, Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathy

Netherlands, Latvia, Italy, France, Portugal, Belgium +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Epileptic Encephalopathy trials by city

Epileptic Encephalopathy in Toronto Epileptic Encephalopathy in Vancouver Epileptic Encephalopathy in Montreal Epileptic Encephalopathy in Calgary Epileptic Encephalopathy in Edmonton Epileptic Encephalopathy in Ottawa Epileptic Encephalopathy in Winnipeg Epileptic Encephalopathy in Quebec City Epileptic Encephalopathy in Hamilton Epileptic Encephalopathy in Kitchener Epileptic Encephalopathy in London Epileptic Encephalopathy in Halifax Epileptic Encephalopathy in New York Epileptic Encephalopathy in Los Angeles Epileptic Encephalopathy in Chicago Epileptic Encephalopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease